We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.
Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million.
⭐️ ABOUT THE SPEAKER
Fabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a CEO-Partner at the US biotech venture capital firm Flagship Pioneering as well as CEO of the Flagship portfolio company Cellarity.
He also served at Novartis and Bristol-Myers-Squibb for 10 years each, with his career beginning in R&D at pharmaceutical companies that were predecessors to today’s Sanofi.
🔗 LINKS MENTIONED
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
